

**Most prescribed insurer lists**

Legislative report	Data year	Drug name - top 10 most prescribed	Therapeutic class	Prescription counts	Note
2025	2024	Amphetamine	ADHD / anti-narcolepsy/ anti-obesity/ anorexiant	213,586	2024 insurer data provided in 2025
2025	2024	Atorvastatin	Antihyperlipidemics	185,523	2024 insurer data provided in 2025
2025	2024	Levothyroxine	Thyroid agents	171,105	2024 insurer data provided in 2025
2025	2024	Bupropion	Antidepressants	166,146	2024 insurer data provided in 2025
2025	2024	Metformin	Antidiabetics	161,716	2024 insurer data provided in 2025
2025	2024	Lisinopril	Antihypertensives	159,183	2024 insurer data provided in 2025
2025	2024	Albuterol	Antiasthmatic and bronchodilator agents	157,926	2024 insurer data provided in 2025
2025	2024	Losartan	Antihypertensives	134,219	2024 insurer data provided in 2025
2025	2024	Sertraline	Antidepressants	132,611	2024 insurer data provided in 2025
2025	2024	Escitalopram	Antidepressants	121,840	2024 insurer data provided in 2025
2024	2023	Atorvastatin calcium	Antihyperlipidemics	185,385	2023 insurer data provided in 2024
2024	2023	Levothyroxine sodium	Thyroid agents	168,754	2023 insurer data provided in 2024
2024	2023	Lisinopril	Antihypertensives	164,576	2023 insurer data provided in 2024
2024	2023	Amphetamine-dextroamphetamine	ADHD / anti-narcolepsy/ anti-obesity/ anorexiant	151,018	2023 insurer data provided in 2024
2024	2023	Metformin HC	Antidiabetics	146,749	2023 insurer data provided in 2024
2024	2023	Bupropion HCl	Antidepressants	145,453	2023 insurer data provided in 2024
2024	2023	Fluzone	Vaccines	131,030	2023 insurer data provided in 2024
2024	2023	Sertraline HCl	Antidepressants	125,994	2023 insurer data provided in 2024
2024	2023	Losartan	Angiotensin receptor blockers	125,620	2023 insurer data provided in 2024
2024	2023	Albuterol sulfate	Antiasthmatic and bronchodilator agents	119,330	2023 insurer data provided in 2024
2023	2022	Influenza virus vaccine	Vaccines	221,220	2022 insurer data provided in 2023
2023	2022	Levothyroxine sodium	Thyroid agents	169,336	2022 insurer data provided in 2023
2023	2022	Atorvastatin calcium	Antihyperlipidemics	166,505	2022 insurer data provided in 2023
2023	2022	Lisinopril	Antihypertensives	161,174	2022 insurer data provided in 2023
2023	2022	Amphetamine-dextroamphetamine	ADHD / anti-narcolepsy/ anti-obesity/ anorexiant	156,001	2022 insurer data provided in 2023
2023	2022	Albuterol sulfate	Antiasthmatic and bronchodilator agents	141,372	2022 insurer data provided in 2023
2023	2022	Metformin HCl	Antidiabetics	137,692	2022 insurer data provided in 2023
2023	2022	Bupropion HCl	Antidepressants	126,612	2022 insurer data provided in 2023
2023	2022	COVID-19 mRNA virus vaccine	Vaccines	124,948	2022 insurer data provided in 2023
2023	2022	Sertraline HCl	Antidepressants	119,432	2022 insurer data provided in 2023
2022	2021	COVID-19 mRNA virus vaccine	Vaccines	537,155	2021 insurer data provided in 2022
2022	2021	Influenza virus vaccine	Vaccines	231,714	2021 insurer data provided in 2022
2022	2021	Atorvastatin calcium	Antihyperlipidemics	194,032	2021 insurer data provided in 2022
2022	2021	Levothyroxine sodium	Thyroid agents	191,047	2021 insurer data provided in 2022
2022	2021	Lisinopril	Antihypertensives	172,584	2021 insurer data provided in 2022
2022	2021	Bupropion HCl	Antidepressants	144,690	2021 insurer data provided in 2022
2022	2021	Metformin HCl	Antidiabetics	140,073	2021 insurer data provided in 2022
2022	2021	Amphetamine-dextroamphetamine	ADHD / anti-narcolepsy/ anti-obesity/ anorexiant	130,632	2021 insurer data provided in 2022
2022	2021	Escitalopram oxalate	Antidepressants	117,177	2021 insurer data provided in 2022
2022	2021	Losartan potassium	Antihypertensives	112,056	2021 insurer data provided in 2022
2021	2020	Levothyroxine	Thyroid agents	251,442	2020 insurer data provided in 2021 - generics
2021	2020	Lisinopril	Antihypertensives	242,400	2020 insurer data provided in 2021 - generics
2021	2020	Atorvastatin	Antihyperlipidemics	237,489	2020 insurer data provided in 2021 - generics
2021	2020	Metformin	Antidiabetics	190,539	2020 insurer data provided in 2021 - generics
2021	2020	Hydrocodone-acetaminophen	Analgesics - Opioid	161,417	2020 insurer data provided in 2021 - generics
2021	2020	Losartan	Antihypertensives	153,488	2020 insurer data provided in 2021 - generics
2021	2020	Bupropion	Antidepressants	147,694	2020 insurer data provided in 2021 - generics
2021	2020	Gabapentin	Anticonvulsants	139,568	2020 insurer data provided in 2021 - generics
2021	2020	Sertraline	Antidepressants	131,018	2020 insurer data provided in 2021 - generics
2021	2020	Amphetamine-dextroamphetamine	ADHD / anti-narcolepsy/ anti-obesity/ anorexiant	129,473	2020 insurer data provided in 2021 - generics
2020	2019	Levothyroxine	Thyroid agents	231,684	2019 insurer data provided in 2020 - top 5 generics
2020	2019	Lisinopril	Antihypertensives	229,247	2019 insurer data provided in 2020 - top 5 generics
2020	2019	Atorvastatin	Antihyperlipidemics	228,075	2019 insurer data provided in 2020 - top 5 generics
2020	2019	Metformin	Antidiabetics	186,926	2019 insurer data provided in 2020 - top 5 generics
2020	2019	Hydrocodone-acetaminophen	Analgesics - Opioid	163,648	2019 insurer data provided in 2020 - top 5 generics

**Most prescribed insurer lists**

<b>Legislative report</b>	<b>Data year</b>	<b>Drug name - top 10 most prescribed</b>	<b>Therapeutic class</b>	<b>Prescription counts</b>	<b>Note</b>
2019	2018	Amlodipine besylate	Cardiovascular agents	Not reported for 2019	2018 insurer data provided in 2019
2019	2018	Atorvastatin calcium	Cardiovascular agents	Not reported for 2019	2018 insurer data provided in 2019
2019	2018	Azithromycin	Antibacterials	Not reported for 2019	2018 insurer data provided in 2019
2019	2018	Hydrochlorothiazide	Cardiovascular agents	Not reported for 2019	2018 insurer data provided in 2019
2019	2018	Hydrocodone-acetaminophen	Analgesics - Opioid	Not reported for 2019	2018 insurer data provided in 2019
2019	2018	Lisinopril	Cardiovascular agents	Not reported for 2019	2018 insurer data provided in 2019
2019	2018	Omeprazole	Cardiovascular agents	Not reported for 2019	2018 insurer data provided in 2019
2019	2018	Proair	Respiratory tract/ pulmonary agents	Not reported for 2019	2018 insurer data provided in 2019
2019	2018	Trazodone hydrochloride	Antidepressants	Not reported for 2019	2018 insurer data provided in 2019
2019	2018	Ventolin	Respiratory tract/ pulmonary agents	Not reported for 2019	2018 insurer data provided in 2019

**Most costly insurer lists**

Legislative report	Data year	Drug name - top 10 highest costs	Therapeutic class	Total annual plan spending	Note
2025	2024	Skyrizi	Dermatologicals	\$37,536,013	2024 insurer data provided in 2025
2025	2024	Keytruda	Antineoplastics and adjunctive therapies	\$36,481,289	2024 insurer data provided in 2025
2025	2024	Stelara	Dermatologicals/ gastrointestinal agents – mis	\$35,685,330	2024 insurer data provided in 2025
2025	2024	Ozempic	Antidiabetics	\$27,326,718	2024 insurer data provided in 2025
2025	2024	Trikafta	Respiratory agents – misc.	\$25,747,283	2024 insurer data provided in 2025
2025	2024	Biktarvy	Antivirals	\$24,080,914	2024 insurer data provided in 2025
2025	2024	Humira	Analgesics – anti-inflammatory	\$23,492,393	2024 insurer data provided in 2025
2025	2024	Entyvio	Gastrointestinal agents – misc.	\$23,070,291	2024 insurer data provided in 2025
2025	2024	Cosentyx	Dermatologicals	\$20,562,420	2024 insurer data provided in 2025
2025	2024	Dupixent	Dermatologicals	\$20,274,398	2024 insurer data provided in 2025
2024	2023	Humira	Analgesics – anti-inflammatory	\$53,267,675	2023 insurer data provided in 2024
2024	2023	Keytruda	Antineoplastics and adjunctive therapies	\$37,816,382	2023 insurer data provided in 2024
2024	2023	Stelara	Dermatologicals	\$31,156,649	2023 insurer data provided in 2024
2024	2023	Biktarvy	Antivirals	\$26,933,839	2023 insurer data provided in 2024
2024	2023	Skyrizi	Dermatologicals	\$25,622,754	2023 insurer data provided in 2024
2024	2023	Entyvio	Gastrointestinal agents	\$21,299,837	2023 insurer data provided in 2024
2024	2023	Enbrel	Analgesics – anti-inflammatory	\$21,147,861	2023 insurer data provided in 2024
2024	2023	Cosentyx	Dermatologicals	\$20,464,979	2023 insurer data provided in 2024
2024	2023	Ozempic	Antihyperglycemic	\$18,232,971	2023 insurer data provided in 2024
2024	2023	Dupixent	Interleukin inhibitors	\$17,124,535	2023 insurer data provided in 2024
2023	2022	Humira	Analgesics – anti-inflammatory	\$75,241,110	2022 insurer data provided in 2023
2023	2022	Stelara	Dermatologicals	\$28,957,943	2022 insurer data provided in 2023
2023	2022	Keytruda	Antineoplastics and adjunctive therapies	\$28,248,898	2022 insurer data provided in 2023
2023	2022	Biktarvy	Antivirals	\$26,988,465	2022 insurer data provided in 2023
2023	2022	Enbrel	Analgesics – anti-inflammatory	\$22,017,823	2022 insurer data provided in 2023
2023	2022	Trikafta	Respiratory agents	\$21,559,651	2022 insurer data provided in 2023
2023	2022	Cosentyx	Dermatologicals	\$18,723,855	2022 insurer data provided in 2023
2023	2022	Entyvio	Gastrointestinal agents	\$17,655,131	2022 insurer data provided in 2023
2023	2022	Inflectra	Gastrointestinal agents	\$16,516,923	2022 insurer data provided in 2023
2023	2022	Skyrizi	Dermatologicals	\$15,517,811	2022 insurer data provided in 2023
2022	2021	Humira	Analgesics – anti-inflammatory	\$76,966,470	2021 insurer data provided in 2022
2022	2021	Stelara	Dermatologicals	\$35,999,195	2021 insurer data provided in 2022
2022	2021	Enbrel	Analgesics – anti-inflammatory	\$28,675,010	2021 insurer data provided in 2022
2022	2021	Biktarvy	Antivirals	\$23,245,660	2021 insurer data provided in 2022
2022	2021	Moderna and Pfizer-BioNTech COVID-19	Vaccines	\$20,679,117	2021 insurer data provided in 2022
2022	2021	Trikafta	Respiratory agents	\$17,964,545	2021 insurer data provided in 2022
2022	2021	Cosentyx	Dermatologicals	\$17,770,873	2021 insurer data provided in 2022
2022	2021	Keytruda	Antineoplastics and adjunctive therapies	\$16,463,259	2021 insurer data provided in 2022
2022	2021	Entyvio	Gastrointestinal agents	\$14,872,464	2021 insurer data provided in 2022
2022	2021	Ocrevus	Psychotherapeutic and neurological agents	\$11,115,070	2021 insurer data provided in 2022
2021	2020	Humira	Analgesics – anti-inflammatory	\$93,544,597	2020 insurer data provided in 2021 - specialty
2021	2020	Enbrel	Analgesics – anti-inflammatory	\$38,306,710	2020 insurer data provided in 2021 - specialty
2021	2020	Stelara	Dermatologicals	\$34,695,952	2020 insurer data provided in 2021 - specialty
2021	2020	Biktarvy	Antivirals	\$27,977,637	2020 insurer data provided in 2021 - specialty
2021	2020	Trikafta	Respiratory agents	\$18,814,841	2020 insurer data provided in 2021 - specialty
2021	2020	Truvada (includes generics)	Antivirals	\$18,498,484	2020 insurer data provided in 2021 - specialty
2021	2020	Cosentyx	Dermatologicals	\$18,098,487	2020 insurer data provided in 2021 - specialty
2021	2020	Keytruda	Antineoplastics and adjunctive therapies	\$16,961,094	2020 insurer data provided in 2021 - specialty
2021	2020	Entyvio	Gastrointestinal agents	\$16,530,321	2020 insurer data provided in 2021 - specialty
2021	2020	Tecfidera (includes generics)	Psychotherapeutic and neurological agents	\$11,842,937	2020 insurer data provided in 2021 - specialty
2020	2019	Humira	Analgesics – anti-inflammatory	\$80,509,117	2019 insurer data provided in 2020
2020	2019	Enbrel	Analgesics – anti-inflammatory	\$33,771,085	2019 insurer data provided in 2020

**Most costly insurer lists**

<b>Legislative report</b>	<b>Data year</b>	<b>Drug name - top 10 highest costs</b>	<b>Therapeutic class</b>	<b>Total annual plan spending</b>	<b>Note</b>
2020	2019	Stelara	Dermatologicals	\$23,399,682	2019 insurer data provided in 2020
2020	2019	Truvada	Antivirals	\$20,608,725	2019 insurer data provided in 2020
2020	2019	Biktarvy	Antivirals	\$18,042,219	2019 insurer data provided in 2020
2020	2019	Rituxan	Antineoplastics and adjunctive therapies	\$16,983,505	2019 insurer data provided in 2020
2020	2019	Cosentyx	Dermatologicals	\$15,746,169	2019 insurer data provided in 2020
2020	2019	Herceptin	Antineoplastics and adjunctive therapies	\$14,072,476	2019 insurer data provided in 2020
2020	2019	Remicade	Gastrointestinal agents	\$13,635,198	2019 insurer data provided in 2020
2020	2019	Opdivo	Antineoplastics and adjunctive therapies	\$13,532,849	2019 insurer data provided in 2020
2019	2018	Herceptin	Antineoplastics	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Rituxan	Antineoplastics	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Genvoya	Antivirals	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Truvada	Antivirals	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Tecfidera	Central nervous system agents	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Cosentyx	Immunological agents	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Enbrel	Immunological agents	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Humira	Immunological agents	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Remicade	Immunological agents	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Stelara	Immunological agents	Not provided in legislative report	2018 insurer data provided in 2019

**Greatest year-over-year increase in plan spending insurer lists**

Legislative report	Data year	Drug name - top 10 greatest increase in plan	Therapeutic class	Year-over-year increase	Note
2025	2024	Skyrizi	Dermatologicals	\$15,701,487	2024 insurer data provided in 2025
2025	2024	Ozempic	Antidiabetics	\$8,934,850	2024 insurer data provided in 2025
2025	2024	Paxlovid	Antivirals	\$7,566,764	2024 insurer data provided in 2025
2025	2024	Nexviazyme	Endocrine and metabolic agents – misc.	\$5,674,528	2024 insurer data provided in 2025
2025	2024	Stelara	Dermatologicals/ gastrointestinal agents – misc.	\$5,370,053	2024 insurer data provided in 2025
2025	2024	Keytruda	Antineoplastics and adjunctive therapies	\$5,332,555	2024 insurer data provided in 2025
2025	2024	Lisdexamfetamine	ADHD / anti-narcolepsy/ anti-obesity/ anorexiant	\$5,121,695	2024 insurer data provided in 2025
2025	2024	Trikafta	Respiratory agents – misc.	\$4,942,366	2024 insurer data provided in 2025
2025	2024	Mounjaro	Antidiabetics	\$4,564,057	2024 insurer data provided in 2025
2025	2024	Dupixent	Dermatologicals	\$4,463,941	2024 insurer data provided in 2025
2024	2023	Keytruda	Antineoplastics and adjunctive therapies	\$13,569,234	2023 insurer data provided in 2024
2024	2023	Skyrizi	Dermatologicals	\$10,452,298	2023 insurer data provided in 2024
2024	2023	Ozempic	Antidiabetics	\$8,708,006	2023 insurer data provided in 2024
2024	2023	Comirnaty	Vaccines	\$5,964,667	2023 insurer data provided in 2024
2024	2023	Prevnar	Vaccines	\$4,735,807	2023 insurer data provided in 2024
2024	2023	Dupixent	Dermatologicals	\$4,510,445	2023 insurer data provided in 2024
2024	2023	Stelara	Dermatologicals	\$4,315,271	2023 insurer data provided in 2024
2024	2023	Verzenio	Antineoplastics and adjunctive therapies	\$3,716,818	2023 insurer data provided in 2024
2024	2023	Jardiance	Antidiabetics	\$2,666,754	2023 insurer data provided in 2024
2024	2023	Entyvio	Gastrointestinal agents – miscellaneous	\$2,327,492	2023 insurer data provided in 2024
2023	2022	Keytruda	Antineoplastics and adjunctive therapies	\$11,840,653	2022 insurer data provided in 2023
2023	2022	Skyrizi	Dermatologicals	\$8,385,287	2022 insurer data provided in 2023
2023	2022	Inflectra	Gastrointestinal agents	\$5,489,239	2022 insurer data provided in 2023
2023	2022	Trikafta	Respiratory agents	\$4,417,699	2022 insurer data provided in 2023
2023	2022	Gammagard	Passive immunizing and treatment agents	\$4,312,556	2022 insurer data provided in 2023
2023	2022	Humira	Analgesics – anti-inflammatory	\$3,682,844	2022 insurer data provided in 2023
2023	2022	Dupixent	Dermatologicals	\$3,333,668	2022 insurer data provided in 2023
2023	2022	Ozempic and Rybelsus (semaglutide)	Antidiabetics	\$3,238,534	2022 insurer data provided in 2023
2023	2022	Stelara	Dermatologicals	\$3,077,394	2022 insurer data provided in 2023
2023	2022	Adcetris	Antineoplastics and adjunctive therapies	\$3,020,976	2022 insurer data provided in 2023
2022	2021	Moderna and Pfizer-BioNTech COVID-19 mRNA	Vaccines	\$17,866,475	2021 insurer data provided in 2022
2022	2021	Stelara	Dermatologicals	\$7,623,454	2021 insurer data provided in 2022
2022	2021	Trikafta	Respiratory agents	\$4,906,302	2021 insurer data provided in 2022
2022	2021	Ozempic and Rybelsus and Wegovy (semaglutide)	Antidiabetics	\$3,092,976	2021 insurer data provided in 2022
2022	2021	Skyrizi	Dermatologicals	\$3,088,360	2021 insurer data provided in 2022
2022	2021	Keytruda	Antineoplastics and adjunctive therapies	\$3,072,226	2021 insurer data provided in 2022
2022	2021	Ocrevus	Psychotherapeutic and neurological agents	\$3,046,577	2021 insurer data provided in 2022
2022	2021	Truvada and generics (Emtricitabine-Tenofovir CR)	Antivirals	\$2,848,130	2021 insurer data provided in 2022
2022	2021	Perjeta	Antineoplastics and adjunctive therapies	\$2,771,539	2021 insurer data provided in 2022
2022	2021	Revlimid	Immunomodulators	\$2,628,811	2021 insurer data provided in 2022
2021	2020	Trikafta	Respiratory agents	\$15,826,660	2020 insurer data provided in 2021 - specialty
2021	2020	Biktarvy	Antivirals	\$10,114,820	2020 insurer data provided in 2021 - specialty
2021	2020	Ultomiris	Hematological agents	\$8,223,291	2020 insurer data provided in 2021 - specialty
2021	2020	Humira	Analgesics – anti-inflammatory	\$6,491,588	2020 insurer data provided in 2021 - specialty
2021	2020	Skyrizi	Dermatologicals	\$5,304,568	2020 insurer data provided in 2021 - specialty
2021	2020	Truxima	Antineoplastics and adjunctive therapies	\$5,291,097	2020 insurer data provided in 2021 - specialty
2021	2020	Stelara	Dermatologicals	\$4,221,864	2020 insurer data provided in 2021 - specialty
2021	2020	Keytruda	Antineoplastics and adjunctive therapies	\$4,002,162	2020 insurer data provided in 2021 - specialty
2021	2020	Mvasi	Antineoplastics and adjunctive therapies	\$3,733,664	2020 insurer data provided in 2021 - specialty
2021	2020	Kanjinti	Antineoplastics and adjunctive therapies	\$3,535,044	2020 insurer data provided in 2021 - specialty
2020	2019	Humira	Analgesics – anti-inflammatory	Not provided in legislative report	2019 insurer data provided in 2020 - top 5 specialty
2020	2019	Keytruda	Antineoplastics and adjunctive therapies	Not provided in legislative report	2019 insurer data provided in 2020 - top 5 specialty
2020	2019	Biktarvy	Antivirals	Not provided in legislative report	2019 insurer data provided in 2020 - top 5 specialty
2020	2019	Cosentyx	Dermatologicals	Not provided in legislative report	2019 insurer data provided in 2020 - top 5 specialty
2020	2019	Stelara	Dermatologicals	Not provided in legislative report	2019 insurer data provided in 2020 - top 5 specialty
2019	2018	Revlimid	Antineoplastics	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Herceptin	Antineoplastics	Not provided in legislative report	2018 insurer data provided in 2019

**Greatest year-over-year increase in plan spending insurer lists**

<b>Legislative report</b>	<b>Data year</b>	<b>Drug name - top 10 greatest increase in plan</b>	<b>Therapeutic class</b>	<b>Year-over-year increase</b>	<b>Note</b>
2019	2018	Opdivo	Antineoplastics	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Mavyret	Antivirals	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Truvada	Antivirals	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Ocrevus	Central nervous system agents	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Humira	Immunological agents	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Stelara	Immunological agents	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Cosentyx	Immunological agents	Not provided in legislative report	2018 insurer data provided in 2019
2019	2018	Symdeko	Respiratory tract/ pulmonary agents	Not provided in legislative report	2018 insurer data provided in 2019

**Link to annual legislative reports**

**Link to legislative reports page**

<https://dfr.oregon.gov/drugtransparency/Pages/annual-reports.aspx>